Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

Delayed Quote. Delayed  - 05/31 10:00:00 pm
71.72 USD   +6.14%
05/31 ALNYLAM PHARMAC : to Webcast Presentations at Upcoming June Investor..
05/26DJIonis's Shares Fall After Co-Developer Opts Against Starting Late..
05/02 ALNYLAM PHARMAC : reports 1Q loss
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/24/2016 05/25/2016 05/26/2016 05/27/2016 05/31/2016 Date
57.81(c) 63.55(c) 70.57(c) 67.57(c) 71.72 Last
580 235 2 010 631 3 118 851 1 238 242 1 344 771 Volume
+3.10% +9.93% +11.05% -4.25% +6.14% Change
More quotes
Financials ($)
Sales 2016 41,7 M
EBIT 2016 -436 M
Net income 2016 -421 M
Finance 2016 583 M
Yield 2016 -
Sales 2017 58,0 M
EBIT 2017 -478 M
Net income 2017 -463 M
Finance 2017 455 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 124x
EV / Sales 2017 91,7x
Capitalization 5 767 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
05/31 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming June Investor Con..
05/26DJIonis's Shares Fall After Co-Developer Opts Against Starting Late-Stage Trial
05/06 ALNYLAM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Hold..
05/02 ALNYLAM PHARMACEUTICALS : reports 1Q loss
05/02 ALNYLAM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Resu..
05/02 ALNYLAM PHARMACEUTICALS : Reports First Quarter 2016 Financial Results and Highl..
04/28 ALNYLAM PHARMACEUTICALS : Reports Complete 18-Month Data from Ongoing Phase 2 Op..
04/28 ALNYLAM PHARMACEUTICALS : to Break Ground on New Manufacturing Facility in Norto..
04/26 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming May Investor Conf..
04/25 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing First Quarter 20..
More news
Sector news : Biotechnology & Medical Research - NEC
05/31 INCYTE : Announces the Launch of the Incyte Charitable Giving Foundation
05/31 QIAGEN NV : Integrates Quality Control Tools into GeneReader NGS System
05/31 VERTEX PHARMACEUTICALS : to Present at the Goldman Sachs Healthcare Conference o..
05/31 GENMAB A/S : Total Number of Voting Rights and Total Share Capital
05/31 GENMAB A/S : Total Number of Voting Rights and Total Share Capital
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/27 BIOTECH FORUM DAILY DIGEST : Relypsa's Good News, Spotlight On Alnylam, Ionis' S..
05/26 Trouble Strikes Ionis; Will It Get Bought Out? By Gilead?
05/26 FDA OKs Behring's single-chain AFSTYLA for hemophilia A
05/26 Ionis' pain is Alnylam's gain, shares up 13%
05/26 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions